Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Moderna

Moderna Inc (NASDAQ: MRNA) shares are trading lower Thursday as vaccine stocks fall in sympathy with Novavax Inc (NASDAQ: NVAX) following reports the FDA's decision on the company's COVID-19 vacci

Benzinga

US Schedules Covid-19 Vaccines For Children Below Five Years

The U.S. government is preparing to launch vaccines for children below five in conjunction with educational and outreach efforts, pending approval by federal regulators, the Wall Street Journal reports. The government looks to provide ten million initial doses as the virus spreads nationwide, leaving the parents anxious. The vaccinations could begin…

Benzinga

Cathie Wood Trims Pfizer Stake And Loads Up $25M In Rival COVID-19 Vaccine Maker

Cathie Wood led Ark Invest on Wednesday initiated a position in Moderna Inc (NASDAQ: MRNA) after the biotech company said an updated version of its COVID-19 booster vaccine appeared to provide strong

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Trials of new COVID vaccine raise hopes of once-a-year booster

Moderna shot is said to produce eightfold increase in antibody levels against Omicron in first four weeks

The Guardian - UK

Moderna vaccine trial raises hopes of yearly Covid booster

People who received vaccine showed significant jump in antibody levels compared to original Moderna jab

The Independent UK

Moderna’s omicron-targeted shot bolsters antibodies in trial

Moderna Inc. said its COVID-19 vaccine that targets omicron generated a “superior” immune response against the variant compared to its original shot in a widely awaited study that could pave the way for another round of boosters in the fall.

Tribune News Service

Moderna's Updated COVID-19 Shot Boosts Omicron Protection

Moderna Inc (NASDAQ: MRNA) has

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Moderna booster update for Omicron variant could be available late summer

The booster contains the original vaccine with an updated version that specifically targets the Omicron variant.

Axios

What's Next For Novavax Stock As COVID Vaccine Clears Key Hurdle In US

After last week's scare stirred by the release of the Food And Drug Administration's briefing documents, Novavax (NASDAQ: NVAX) can now heave a sigh of relief.

Benzinga

Moderna announces promising results from next-generation Covid vaccine trials

Experts hope the newer jabs could protect against a wider range of variants.

The Independent UK

Moderna says its new vaccine booster shows 'superior' response to omicron

The "bivalent" vaccine — meaning it targets two different antigens — is Moderna's leading candidate for an effective booster this fall. If the data pan out, it could lead to a yearly booster.

WEKU

Moderna says updated COVID shot boosts omicron protection

Moderna says its experimental COVID-19 vaccine that combines its original shot with protection against the omicron variant appears to work

The Independent UK

Moderna Says Omicron-Specific Booster Generates Strong Immune Response

Moderna Inc said on Wednesday its COVID-19 vaccine booster that targets both the original coronavirus strain and Omicron produced a better immune response against the variant than its original vaccine. The booster raised virus-neutralizing antibodies by eight-fold in a study.

Asharq Al-Awsat

Moderna says Omicron-targeted COVID shot shows better response

Moderna Inc said on Wednesday a new version of its coronavirus vaccine produced a better immune response against Omicron than the original shot, as the drugmaker pursues a booster against a surge in infections in the fall season.

Reuters

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Expert Ratings for Moderna

Within the last quarter, Moderna (NASDAQ:MRNA) has observed the following analyst ratings:

Benzinga

The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Moderna Commences Late-stage Study of Flu Vaccine Candidate

Moderna, Inc. (NASDAQ: MRNA) today announced Initiation of Patient dosing in the phase 3 clinical study of its seasonal influenza vaccine candidate mRNA-1010 for patients with influenza.

The Philadelphia Inquirer

Kids under 5 should soon have access to COVID vaccines, but many parents are likely to say, I don’t feel comfortable'

PHILADELPHIA — Zoli’s parents plan to get their 4-year-old son vaccinated against COVID-19 as soon as shots for young children could finally become available later this month.

Get all your
news in one place.

100's of premium titles.
One news app.

The Conversation

We still need a vaccine patent waiver, but not the one on offer at the World Trade Organization meeting

In mid-June, the World Trade Organization (WTO) will meet to finish negotiations to waive certain sections of the agreement on Trade Related Intellectual Property Rights (TRIPS). However, it is not the TRIPS waiver originally proposed 18 months ago by member states South Africa and India, which would have allowed countries…

The Independent UK

NOT REAL NEWS: A look at what didn't happen this week

Social media users shared a range of false claims this week

Wales Online

Covid vaccines for the under-fives - what parents need to know

Children under five represent the only age group yet to have a vaccine approved for use

Benzinga

Pfizer Seeks FDA Approval For Three Covid Vaccine Doses For Children Below Five

Partners Pfizer, Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) urged the FDA to authorize three vaccine doses for children below five, the Wall Street Journal reports. The companies previously asserted that three doses of the shot were 80% effective at preventing symptomatic Covid-19 with robust immune response in children between six months to five years. After mixed results…

Reuters

Japan study shows women more likely to get skin rash from Moderna shot

A study in Japan found that women were significantly more likely than men to develop rash-like side effects after a first dose of Moderna Inc's COVID-19 vaccine.

Benzinga

Check Out What Whales Are Doing With MRNA

Someone with a lot of money to spend has taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

The Conversation

COVID vaccines for children under five: what parents need to know

Pfizer’s COVID-19 vaccine became available for children aged five to 11 in the UK in April 2022. Those aged 12 and up had already been eligible since 2021.

1 … 23 24 25 26

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Centers for Disease Control and Prevention

Read news from The Economist, FT, and more,
with one subscription

Topics

Intellectual Property

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.